Optibrium demonstrates accelerated lead optimization in complex agrochemical development

Optibrium, a leading developer of software and AI solutions for molecular design today announced the publication of a peer-reviewed study in Journal of Computer-Aided Molecular Design, ‘From UK-2A to florylpicoxamid: Active learning to identify a mimic of a macrocyclic natural product’. The paper demonstrates the successful application of the QuanSA (Quantitative Surface-field Analysis) method, part of Optibrium’s BioPharmics platform for 3D molecular design, to accelerate the lead optimization of a complex macrocyclic natural product during agrochemical development. By significantly reducing the number of synthetic steps required during optimization, the study supports the commercial viability of complex macrocyclic compounds.

Optibrium’s QuanSA method uses an active learning approach that combines two types of molecular selection—the first identifies compounds predicted to be most active, and the second identifies compounds predicted to be most informative for lead optimization. The method has broad applications in lead optimization where scaffold replacements are needed, from agrochemical development to small molecule and macrocyclic ligand design and discovery. In the study together with a leading agriculture company, Optibrium explored how this approach could provide a more efficient route to finding new agrochemicals (e.g., for crop protection) by reducing the number of compounds requiring synthesis.

Florylpicoxamid (FPX) is a mimic of a macrocyclic natural product, UK-2A, originally identified through a stepwise deconstruction method that required thousands of synthetic analogues alongside in vitro and in planta assays. Using the QuanSA method, the binding metabolic form of FPX was successfully identified within five rounds of compound selection and model refinement, reducing the total number of required synthetic analogues by a factor of ten.

Purely ligand-based affinity prediction is challenging, with the presence of macrocycles compounding the complexity. We are excited to show how machine learning can build physically meaningful models for lead optimization and how Optibrium’s QuanSA method, using an active learning strategy, can be applied to real-world molecular design.” 

​​​​​​​Ann Cleves, VP of Application Science, Optibrium

​​​​​​​Ann continues: “Macrocyclic natural products show great promise as drugs and in crop protection, but their complexity makes them difficult to synthesize and implement on a large-scale. This study demonstrates that we can greatly simplify the lead optimization of complex molecules not only for drug discovery but to drive new agrochemical development.”

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Optibrium Ltd.. (2024, July 02). Optibrium demonstrates accelerated lead optimization in complex agrochemical development. News-Medical. Retrieved on December 24, 2024 from https://www.news-medical.net/news/20240702/Optibrium-demonstrates-accelerated-lead-optimization-in-complex-agrochemical-development.aspx.

  • MLA

    Optibrium Ltd.. "Optibrium demonstrates accelerated lead optimization in complex agrochemical development". News-Medical. 24 December 2024. <https://www.news-medical.net/news/20240702/Optibrium-demonstrates-accelerated-lead-optimization-in-complex-agrochemical-development.aspx>.

  • Chicago

    Optibrium Ltd.. "Optibrium demonstrates accelerated lead optimization in complex agrochemical development". News-Medical. https://www.news-medical.net/news/20240702/Optibrium-demonstrates-accelerated-lead-optimization-in-complex-agrochemical-development.aspx. (accessed December 24, 2024).

  • Harvard

    Optibrium Ltd.. 2024. Optibrium demonstrates accelerated lead optimization in complex agrochemical development. News-Medical, viewed 24 December 2024, https://www.news-medical.net/news/20240702/Optibrium-demonstrates-accelerated-lead-optimization-in-complex-agrochemical-development.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Optibrium appoints Ian Smith as Chief Technology Officer